Nanograb
Nanograb is a computational drug discovery company that uses AI to create novel targeted non-viral gene therapy vectors. Our platform designs unique combinations of small peptide binders attached to nanoparticles to safely deliver genetic medicines to specific cells and tissues in the body at scale.
Y Combinator
yc-company-directory #2500Nanograb is a computational drug discovery company that uses AI to create novel targeted non-viral gene therapy vectors. Our platform designs unique combinations of small peptide binders attached to nanoparticles to safely deliver genetic medicines to specific cells and tissues in the body at scale.
sourceNanograb is classified as AI infrastructure from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to Nanograb
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
Origami Therapeutics, Inc.
match 72Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our proprietary human disease models developed to select the small molecules with the best chance of clinical success. Our first indication is Huntington’s disease, a debilitating, progressive and ultimately fatal disorder caused by a genetic mutation. We have already identified sm
shared extracted concept terms: drug, discovery; shared product terms: drug, discovery, novel, small; same category: AI infrastructure; shared affiliation: Y Combinator
Numerion Labs
match 66Numerion Labs is an AI-native company accelerating the discovery of life-saving medicines through the development and use of cutting-edge machine learning algorithms. The company unites computational chemistry, structural biology, and medicinal chemistry to pioneer the next generation of AI-driven drug discovery platforms.
shared extracted concept terms: computational, drug, discovery; shared product terms: computational, drug, discovery, medicine; same category: AI infrastructure; shared affiliation: Y Combinator
NeuroX1
match 65Computational drug discovery leveraging generative AI to create therapeutics for neurodegenerative disorders.
shared extracted concept terms: computational, drug, discovery; shared product terms: computational, drug, discovery, create; same category: AI infrastructure
Eugit Therapeutics
match 60Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator
shared product terms: target, non, specific, drug; same category: AI infrastructure; shared affiliation: Y Combinator
Modulari-T
match 52Cell and gene therapy promises to one day cure any disease; Modulari-T’s Platform produces the tools to fulfill that promise. Modulari-T has designed a new family of synthetic genes that can reprogram cells to better sense their environment and modify their behavior accordingly. This can be used to engineer immune cells to efficiently recognize and kill cancer cells or to create stem cells able to regenerate any tissue. Modulari-T looks to expand its technology to reach every area of cell therap
shared product terms: cell, gene, therapy, design; same category: AI infrastructure; shared affiliation: Y Combinator
Nuntius Therapeutics
match 33Cell-specific genetic medicines
shared product terms: cell, specific, genetic, medicine; shared affiliation: Y Combinator